5788-60-3 Usage
Uses
Used in Pharmaceutical Industry:
3-Chloro-6-Propyloxypyridazine is used as a potential active pharmaceutical ingredient for its antimicrobial properties, which can be harnessed to combat various bacterial infections. Its ability to inhibit bacterial growth makes it a candidate for the development of new antibiotics.
Used in Anti-inflammatory Applications:
In the field of anti-inflammatory research, 3-Chloro-6-Propyloxypyridazine may be utilized as a compound with potential anti-inflammatory effects. This could be beneficial in the treatment of conditions characterized by inflammation, such as arthritis or other inflammatory disorders.
Used in Analgesic Formulations:
3-Chloro-6-Propyloxypyridazine is used as a component in analgesic formulations, leveraging its potential pain-relieving properties. This could contribute to the development of new medications for the management of pain, including chronic and acute conditions.
Used in Antipyretic Medicines:
As an antipyretic, 3-Chloro-6-Propyloxypyridazine is used in medicines designed to reduce fever. Its capacity to lower body temperature during episodes of fever can be an essential aspect of treatment for various illnesses.
Check Digit Verification of cas no
The CAS Registry Mumber 5788-60-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,7,8 and 8 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 5788-60:
(6*5)+(5*7)+(4*8)+(3*8)+(2*6)+(1*0)=133
133 % 10 = 3
So 5788-60-3 is a valid CAS Registry Number.
InChI:InChI=1/C7H9ClN2O/c1-2-5-11-7-4-3-6(8)9-10-7/h3-4H,2,5H2,1H3
5788-60-3Relevant academic research and scientific papers
N-phenyl-4-pyrazolo[1,5-6]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy
Tavares, Francis X.,Boucheron, Joyce A.,Dickerson, Scott H.,Griffin, Robert J.,Preugschat, Frank,Thomso, Stephen A.,Wang, Tony Y.,Zhouf, Hui-Qiang
, p. 4716 - 4730 (2007/10/03)
Glycogen synthase kinase 3 regulates glycogen synthase, the rate-determining enzyme for glycogen synthesis. Liver and muscle glycogen synthesis is defective in type 2 diabetics, resulting in elevated plasma glucose levels. Inhibition of GSK-3 could potentially be an effective method to control plasma glucose levels in type 2 diabetics. Structure-activity studies on a N-phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine series have led to the identification of potent and selective compounds with good cellular efficacy. Molecular modeling studies have given insights into the mode of binding of these inhibitors. Since the initial leads were also potent inhibitors of CDK-2/CDK-4, an extensive SAR was performed at various positions of the pyrazolo[1,5-b] pyridazin core to afford potent GSK-3 inhibitors that were highly selective over CDK-2. In addition, these inhibitors also exhibited very good cell efficacy and functional response. A representative example was shown to have good oral exposure levels, extending their utility in an in vivo setting. These inhibitors provide a viable lead series in the discovery of new therapies for the treatment of type 2 diabetes.
